Possible mechanisms of action of (-)deprenyl and other MAO-B inhibitors in some neurologic and psychiatric disorders.
Berry
M D
MD
Neuropsychiatric Research Unit, University of Saskatchewan, Saskatoon, Canada.
Juorio
A V
AV
Paterson
I A
IA
D000375:Aging; D000544:Alzheimer Disease / Q000188:drug therapy / Q000503:physiopathology; D000818:Animals; D003072:Cognition Disorders / Q000188:drug therapy; D003866:Depressive Disorder / Q000188:drug therapy; D006801:Humans; D008136:Longevity; D001523:Mental Disorders / Q000188:drug therapy* / Q000503:physiopathology*; D008996:Monoamine Oxidase Inhibitors / Q000627:therapeutic use*; D009422:Nervous System Diseases / Q000188:drug therapy* / Q000503:physiopathology; D010300:Parkinson Disease / Q000188:drug therapy / Q000503:physiopathology; D012559:Schizophrenia / Q000188:drug therapy; D012642:Selegiline / Q000494:pharmacology / Q000627:therapeutic use*
D008996:Monoamine Oxidase Inhibitors; D012642:Selegiline